Please ensure Javascript is enabled for purposes of website accessibility

3 Stocks That Could Put Amazon's Returns to Shame

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Looking for stocks with lots of upside potential? These three high-growth companies have you covered.

Amazon (AMZN 3.15%) has been the quintessential growth stock for nearly a generation. However, the company's market cap currently exceeds $570 billion. That's an enormous figure that will make it hard for the company to produce eye-popping gains from here.

There are some growth stocks that may be able to put Amazon's returns to shame going forward. We asked a team of Motley Fool investors to weigh in, and they picked Aphria (NASDAQOTH: APHQF), Sunpower (SPWR -1.01%), and NovoCure (NVCR 5.47%)

Coins stacked to look like rocket ship

Image source: Getty Images.

A high-flyer marijuana stock for bold investors

Neha Chamaria (Aphria): It's not easy to replicate Amazon's exponential growth, but there's one stock north of the border that absolutely crushed the e-commerce giant during the year: Aphria, Inc. And it could continue to do so given the red-hot industry in which it operates. Check out the Canadian cannabis stock's jaw-dropping run-up in recent months:

AMZN Chart

AMZN data by YCharts.

While Aphria's run-up is insane, it isn't all a fluke. Medical cannabis is already legal in Canada, and Aphria is a licensed Health Canada medical-marijuana producer, and among the largest players in the industry. What's striking is that Aphria is already profitable, unlike most of its peers, and is growing its bottom line at a torrid pace. For instance, Aphria's net income surged to $15 million Canadian during its last-reported quarter ended August 31, 2017 from only CA$0.9 million in the year-ago period. Aphria's dried cannabis cash and all-in costs are also declining steadily. 

Aphria's pace of growth looks like it's here to stay, given its aggressive efforts to expand its foothold. The company just took a big leap forward by striking a deal with Loblaw Companies' retail-pharmacy chain, Shoppers Drug Mart, to supply medical cannabis for online sale, subject to the chain gaining approval as a licensed cannabis producer. Aphria is already expanding its capacity in anticipation of rising demand for medical pot, but the opportunities could be even bigger if Canada legalizes recreational marijuana in 2018, as planned.

Given the backdrop, it isn't unreasonable to expect Aphria's sales and profits to continue to grow if the marijuana markets open up. As they do, so should the stock price.

A renewable future

Jeremy Bowman (Sunpower Corporation): It's not going to be easy to put Amazon's returns to shame. The e-commerce giant has returned an incredible 60,000% since its 1997 initial public offering (IPO), and has surged 1,300% over the last decade. In order to find a stock capable of such phenomenal returns, investors have to look to a space with huge potential growth, and I think the solar sector and Sunpower fit the bill.

It's clear that renewables, led by solar, are the future of energy consumption. As technology improves, and the world moves away from environmentally harmful fossil fuels, wind and solar will gradually take over. Today, there are many solar manufacturers fighting for market share, as other emerging technologies have in the past. However, the industry should eventually shake out the weak players, leaving a few big winners.

Sunpower is primed to be one such winner as it's a leader in efficiency, which gives it an edge over a number of other competitors. The company also operates in most major solar markets around the world, which should give it an advantage. As solar has gotten cheaper, it has become more popular in developing regions like India and the Middle East. Sunpower also has a stronger balance sheet than many of its peers, which should help it outlast them as the industry moves toward profitability and maturity.

Sunpower's history on the stock market has not been reassuring so far, as the stock has fallen considerably over the last couple of years. Remember, however, that Amazon crashed, too, when the dot-com bubble burst, and has had a number of pullbacks over its history. It, too, also operated for much of its history without making a profit. 

The risk/reward profile for Sunpower is high, but it could pay off with huge returns if it wins the battle for solar supremacy.

A new tool in the cancer fight

Brian Feroldi (NovoCure): Physicians have used surgery, radiation, and chemotherapy to fight cancer for decades. While these modalities are effective in treating some types of cancer, they're still woefully inadequate in others.

Glioblastoma multiforme (brain cancer) is one type of cancer where current treatment options still fall short. That's where an innovative healthcare company called NovoCure comes into the picture. NovoCure developed a brand new modality of treatment called tumor treating fields (TTFields) that's giving brain cancer patients new hope. 

While the science behind TTFields is a bit complex, the most important takeaways for investors to know is that TTFields are clinically proven to work and are virtually free of side effects. That's a highly compelling combination for potential patients.

Given the advantages, NovoCures's growth has been nothing short of explosive since TTFields received Food and Drug Administration approval a few years ago. As an example, last quarter, Novocure's revenue soared 131%, to $50 million. That marked the ninth quarter in a row that the company put up triple-digit top-line growth.

While NovoCure's growth has been very impressive over the last few years, there's actually ample reason to believe that the company is just getting started. NovoCure believes that TTFields can be used to treat a range of other cancer types, such as lung, ovarian, and pancreatic. If true, then this company's top line -- and stock price -- could be poised for explosive growth for years to come.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

SunPower Corporation Stock Quote
SunPower Corporation
SPWR
$15.65 (-1.01%) $0.16
NovoCure Stock Quote
NovoCure
NVCR
$73.30 (5.47%) $3.80
Amazon.com, Inc. Stock Quote
Amazon.com, Inc.
AMZN
$109.56 (3.15%) $3.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.